GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Recommendation of “Moderate Buy” by Analysts

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been assigned a consensus recommendation of “Moderate Buy” from the twenty brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $9.32.

A number of research analysts recently issued reports on the stock. Raymond James raised shares of GoodRx from a “market perform” rating to an “outperform” rating and set a $10.00 price objective on the stock in a research note on Thursday, May 16th. Royal Bank of Canada raised GoodRx from a “sector perform” rating to an “outperform” rating and increased their target price for the company from $8.00 to $10.00 in a report on Thursday, May 23rd. Wells Fargo & Company upgraded shares of GoodRx from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $7.50 to $10.00 in a research report on Monday, March 25th. Morgan Stanley increased their price target on GoodRx from $7.00 to $9.50 and gave the stock an “equal weight” rating in a research note on Monday, June 10th. Finally, Barclays increased their price objective on shares of GoodRx from $9.00 to $10.00 and gave the company an “overweight” rating in a report on Monday, May 20th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in GDRX. Stifel Financial Corp lifted its position in shares of GoodRx by 0.8% during the third quarter. Stifel Financial Corp now owns 346,797 shares of the company’s stock worth $1,952,000 after purchasing an additional 2,920 shares in the last quarter. Gotham Asset Management LLC grew its position in GoodRx by 121.6% in the 3rd quarter. Gotham Asset Management LLC now owns 72,090 shares of the company’s stock valued at $406,000 after buying an additional 39,552 shares in the last quarter. Sectoral Asset Management Inc. acquired a new stake in shares of GoodRx in the 3rd quarter worth approximately $5,669,000. Rip Road Capital Partners LP boosted its stake in GoodRx by 45.1% during the 3rd quarter. Rip Road Capital Partners LP now owns 1,401,983 shares of the company’s stock valued at $7,893,000 after purchasing an additional 435,883 shares in the last quarter. Finally, Citigroup Inc. lifted its holdings in GoodRx by 301.7% in the 3rd quarter. Citigroup Inc. now owns 7,997 shares of the company’s stock valued at $45,000 after acquiring an additional 6,006 shares during the last quarter. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Trading Up 1.4 %

NASDAQ:GDRX opened at $7.80 on Friday. GoodRx has a 1 year low of $4.14 and a 1 year high of $9.37. The stock’s fifty day moving average price is $7.61 and its two-hundred day moving average price is $6.96. The company has a debt-to-equity ratio of 1.02, a current ratio of 6.29 and a quick ratio of 6.29. The company has a market cap of $2.93 billion, a P/E ratio of -779.22, a P/E/G ratio of 3.58 and a beta of 1.40.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings data on Thursday, May 9th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.01). The company had revenue of $197.88 million for the quarter, compared to analysts’ expectations of $196.20 million. GoodRx had a negative net margin of 0.86% and a positive return on equity of 3.45%. As a group, analysts expect that GoodRx will post 0.17 EPS for the current year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.